Heike Keilhack

6.9k citations
51 papers · 5.8k · 4 hit papers · h-index 32

Impact in

    • Epigenetics and DNA Methylation
    • Protein Tyrosine Phosphatases
    • Chromatin Remodeling and Cancer
    • Cancer-related gene regulation
    • Protein Degradation and Inhibitors
    • Protein Kinase Regulation and GTPase Signaling
  • Oncology top 5%

Papers in

    • Epigenetics and DNA Methylation 17
    • Protein Tyrosine Phosphatases 10
    • Chromatin Remodeling and Cancer 10
    • Cancer-related gene regulation 6
    • PI3K/AKT/mTOR signaling in cancer 3
    • Protein Degradation and Inhibitors 2
    • Lymphoma Diagnosis and Treatment 6

Heike Keilhack

50 papers receiving 5.6k citations

Heike Keilhack's Hit Papers

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study 2018 · 522 citations
5220+4+9Years since publication200400600

Peers

Heike Keilhack
Comparison fields: 5 of 89
  • Molecular Biology 3.7k
  • Oncology 546
  • Pathology and Forensic Medicine 382
  • Immunology and Allergy 104
  • Genetics 161
Replace Vesselina G. Cooke with:
Vesselina G. Cooke United States
Robert A. Blake China
Italia Bongarzone Italy
Kurt R. Auger United States
Julie Nardone United States
Kenna Lynn Anderes United States
Bruce W. Konicek United States
James Robert Bischoff Spain
Gabriella Zupi Italy
Dale L. Ludwig United States
Heike Keilhack relative to Vesselina G. Cooke United States Vesselina G. Cooke's profile →
Citations per field
00.5×1.5×1.9×
Vesselina G. Cooke · 1×
Citations per year

Countries citing papers authored by Heike Keilhack

Since Specialization
Citations

This map shows the geographic impact of Heike Keilhack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heike Keilhack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heike Keilhack more than expected).

Fields of papers citing papers by Heike Keilhack

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heike Keilhack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heike Keilhack. The network helps show where Heike Keilhack may publish in the future.

Co-authors

The 25 scholars most cited alongside Heike Keilhack, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Heike Keilhack Line = papers co-authored together Heike Keilhack links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.

#Work
1
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Hit paper breakdown →
2012663
2
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
Hit paper breakdown →
2013661
3
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Hit paper breakdown →
2018522
4
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 -Mutant Non-Hodgkin Lymphoma
Hit paper breakdown →
2014460
5 2004441
6 2015302
7 2005251
8 2005234
9 2017149
10 2016145
11 2021129
12 1998128
13 2001127
14 2012126
15 2015112
16 2016112
17 1999106
18 201699
19 200993
20 199791

About Heike Keilhack

Heike Keilhack is a scholar working on Molecular Biology, Pathology and Forensic Medicine, Oncology, Genetics and Hematology, having authored 51 papers that have together received 5.8k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (17 papers), Protein Tyrosine Phosphatases (10 papers), Chromatin Remodeling and Cancer (10 papers), Cancer-related gene regulation (6 papers), Lymphoma Diagnosis and Treatment (6 papers), PARP inhibition in cancer therapy (5 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Protein Degradation and Inhibitors (2 papers). The work is most often cited by research in Molecular Biology (3.7k citations), Oncology (546 citations), Pathology and Forensic Medicine (382 citations), Immunology and Allergy (104 citations) and Genetics (161 citations). Heike Keilhack has collaborated with scholars based in United States, Germany and Japan. Frequent co-authors include Robert A. Copeland, Sarah K. Knutson, Tim J. Wigle, Kevin W. Kuntz, Frank‐D. Böhmer, Mikel P. Moyer, Richard Chesworth, Victoria M. Richon, Benjamin G. Neel and Roy M. Pollock. Their work appears in journals such as Journal of Biological Chemistry, Blood, Molecular Cancer Therapeutics, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact